SBRT 2016

Phase II or retrospective cohorts

Author/year

Design

# mCRC pts. Lung/liver/LN

Fract x dose

Local control 2 years

Survival 2 years

3 x 9.2-20Gy (NTCP-based)

Lee 2009

Phase I

40/68

0/40/0

(-)

35%

Van der Pool 2010

Phase I/II

20

0/20/0

3 x 12.5Gy

74%

83%

Kang 2010

Retrospect

59

13/10/31

3 x 12-17Gy

65%

65%

Chang 2011

Phase I/II Retrospect

65 41

0/65/0

1x22-3x20 Gy 3 x 15-20 Gy

55% 76%

38% 68%

Bae 2012

12/11/18

Van den Begin 2014 Filippi 2014 Comito 2014 Thibault 2014 De Vin 2014 Takahachi 2014 Carbon ions

4-5 x 10 Gy (isocenter)

53%(lung/liver) 79% (LN) 1-year

Retrospect

47

NA

65%*

Retrospect

40 82

40/0/0 60/52/0

1 x 26-4 x 12 Gy 4 x 12-3 x 25Gy

NA

73% 65%

Phase II

80% 76% 33%

Retrospect Retrospect

45/83

4 x 12-20 Gy 10 x 4-5 Gy

72%*

103/309

56/77/176

32% (3-year)

Feasibility

34

34/0/0

4 x 13.2-15 GyE

85%

65%

Qiu 2015

Retrospect

64

42/NA/NA

10x5Gy or 5x10Gy

31%

43%

3 x 15-22.5 Gy (isocenter)

Fode 2015

Retrospect

201

30/165/6

LR: 13%

58%